14
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Soluble CD95 in the Serum of Patients with Low and Intermediate Grade Malignant Lymphomas: Absence of Prognostic Correlations

, , &
Pages 517-521 | Accepted 07 Feb 1997, Published online: 01 Jul 2009

References

  • Harris N. L., Jaffe E. S., Stein H., et al. A revised European‐American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1993; 84: 1361–1392
  • International Non‐Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non‐Hodgkin's lymphoma. N. Engl. J. Med. 1993; 329: 987–994
  • Seymour J. F., Talpaz M., Cabanillas F., Wetzler M., Kurzrock R. Serum interleukin‐6 levels correlate with prognosis in diffuse large‐cell lymphoma. J. Clin. Oncol. 1995; 13: 575–582
  • Cortes J. E., Talpaz M., Cabanillas F., Seymour J. F., Kurzrock R. Serum levels of interleukin‐10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood. 1995; 85: 2516–2520
  • Smith C. A., Farrah T., Goodwin R. G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76: 959–962
  • Dhein J., Walczak H., Baumler C., Debatin K. M., Krammer P. H. Autocrine T‐cell suicide mediated by Apo‐1 (Fas/CD95). Nature 1995; 373: 438–441
  • Owen‐Schaub L., Yonehara S., Grump W. L., Grimm E. A. DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell. Immunol. 1992; 140: 197–140
  • Reed J. C. Bcl‐2: prevention of apoptosis as a mechanism of drug resistance. Hem/One Clin NA. 1995; 9: 451–473
  • Cheng J., Zhou T., Liu C., Shapiro J. P., Brauer M. J., Kiefer M. C., Barr P. J., Mountz J. D. Protection from Fas‐mediated apoptosis by a soluble form of the Fas molecule. Science. 1994; 263: 1759–1762
  • Cascino I., Fiucci G., Papoff G., Ruberti G. Three functional soluble forms of the human apoptosis‐inducing Fas molecule are produced by alternative splicing. J Immunol. 1995; 154: 2706–2713
  • Knipping E., Debatin K. M., Strieker K., Heilig B., Eder A., Krammer P. H. Identification of soluble APO‐1 in supernatants of human B‐ and T‐cell lines and increased serum levels in B‐ and T‐cell leukemias. Blood 1995; 85: 1562–1569
  • Salles G., Bienvenu J., Bastion Y., Barbier Y., Doche C., Warzocha K., Gutowski M. C., Rieux C., Coiffier B. Elevated circulating levels of TNFα and its p55 soluble receptor are associated with an adverse prognosis in lymphoma patients. Brit. J. Haematol. 1996; 93: 352–359
  • Denz H., Orth B., Weiss G., Gallati H., Herrmann R., Huber P., Wachter H., Fuchs D. Serum soluble tumour necrosis factor 55 is increased in patients with haema‐tological neoplasias and is associated with immune activation and weight loss. Eur. J. Cancer 1993; 16: 2232–2235
  • Nadali G., Vinante F., Stein H., Todeschini G., Tecchio C., Morosato L., Chilosi M., Menestrina F., Kinney M. C., Greer J. P., Latza U., Perona G., Pizzolo G. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large‐cell lymphoma. J. Clin. Oncol. 1995; 13: 1355–1360
  • Motokura T., Kobayashi Y., Fujita A., Nakamura Y., Taniguchi T., Uchimaru K., Ansano S. Clinical relevance of serial measurement of the serum levels of soluble interleukin‐2 receptor and soluble CD8 in malignant lymphoma. Leukemia and Lymphoma 1995; 16: 355–362
  • Stasi R., Zinzani P. L., Galieni P., Lauta V. M., Damasio E., Dispensa E., Dammaco F., Papa G., Tura S. Prognostic value of serum IL‐10 and soluble IL‐2 receptor levels in aggressive non‐Hodgkin's lymphoma. Brit. J. Haematol. 1994; 88: 770–777
  • Lavabre‐Bertrand T., Exbrayat C., Liautard J., Gaillard J. P., Baskevitch P. P., Poujol N., Duperay C., Bourquard P., Brochier J. Detection of membrane and soluble interleukin‐6 receptor in lymphoid malignancies. Brit. J. Haematol. 1995; 91: 871–877
  • Munker R., Dimis G., Owen‐Schaub L., Andreeff M. Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes. Leukemia 1996; 10: 1531–1533
  • Kondo E., Yoshino T., Yamadori I., Matsuo Y., Kawasaki N., Minowada J., Akagi T. Expression of bcl‐2 protein and Fas antigen in non‐Hodgkin's lymphomas. Am J Pathol. 1994; 145: 330–337
  • Nishiuchi R., Yoshino T., Matsuo Y., Sakuma I., Cao L., Seino Y., Takahashi K., Akagi T. The Fas antigen is detected on immature B cells and the representative cell lines show Fas‐mediated apoptosis. Brit. J. Haematol. 1996; 92: 302–307
  • Danis V. A., Millington M., Hyland V. J., Grennan D. Cytokine production by normal human monocytes: inter‐subject variation and relationship to an IL‐1 receptor antagonist (IL‐1rA) gene polymorphism. Clin Exp Immunol. 1995; 99: 303–310

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.